Evicenter
Trodelvy (sacituzumab govitecan-hziy) in Metastatic triple-negative breast cancer
Manufacturer
Gilead Sciences, Inc.
Prescribing information
Trodelvy (opens in a new tab)
Questions
47
Last updated

All questions

Clinical trials: Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer

7 questions · 5 sources

ASCENT trial

How was the TRODELVY ASCENT trial in previously treated metastatic TNBC designed?

TRODELVY vs chemotherapy in metastatic TNBC (ASCENT): what was median progression-free survival?

Note: The full-population result appears under the Full Population PFS tab of the same page.

How long did TRODELVY patients live compared with chemotherapy in metastatic TNBC (ASCENT)?

ASCENT-03 trial

How effective is first-line TRODELVY when PD-1/PD-L1 inhibitors are not an option (ASCENT-03)?

What is the first-line TRODELVY response rate (ASCENT-03)?

ASCENT-04 trial

How effective was first-line TRODELVY plus pembrolizumab for PD-L1-positive metastatic TNBC (ASCENT-04)?

Note: On this page the 12-month PFS sentence cites reference 2, which the page lists as the ASCENT-03 publication (Cortés et al., N Engl J Med 2025); the study design passage cites reference 3, the ASCENT-04 publication (Tolaney et al., N Engl J Med 2026).

What is the first-line TRODELVY plus pembrolizumab response rate (ASCENT-04)?